TABLE 9.

Clinical trials with farletuzumab in ovarian cancer.

Name of the study	Year of the study	Phase of the study	Research group	Dose of farletuzumab	Results
Konner et al. (Konner et al., 2010)	2010	I	25 (at least one infusion of farletuzumab)	Escalating dose of 12.5–400 mg/m2 on days 1, 6, 15 and 22 of a 5-day cycle	Stable disease by Response Evaluation Criteria in Solid Tumors observed in 9 (36%) patients and CA-125 reduction in 4
Armstrong et al. (Armstrong et al., 2013)	2013	Phase II	47, (combination therapy with farletuzumab)	100 mg/m2, once weekly	Total or partial ORR was 75% with combination therapy
Vergote et al. (Vergote et al., 2016)	2016	III	1,091, (placebo group n = 352, farletuzumab 1.25 mg/kg group n = 376, farletuzumab 2.5 mg/kg group n = 363)	1.25 mg/kg or 2.5 mg/kg	Placebo group, farletuzumab 1.25 mg/kg group, farletuzumab 2.5 mg/kg group: PFS 9.0, 9.5, 9.7 months; OS 29.1, 28.7, 32.1 months, respectively
Herzog et al. (Herzog et al., 2023)	2023	II	214, (farletuzumab plus chemotherapy group n = 142, placebo plus chemotherapy group n = 72)	5 mg/kg weekly	Farletuzumab plus chemotherapy group, placebo plus chemotherapy: PFS 11.7, 10.8 months, respectively

ORR, overall response rate; PFS, progression-free survival; OS, overall survival.